These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

827 related items for PubMed ID: 21956718

  • 1. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.
    Ito D, Suzuki N.
    Neurology; 2011 Oct 25; 77(17):1636-43. PubMed ID: 21956718
    [Abstract] [Full Text] [Related]

  • 2. [Conjoint pathological cascades mediated by RNA-binding proteins, TDP-43, FUS and ataxin-2].
    Ito D.
    Rinsho Shinkeigaku; 2012 Oct 25; 52(11):1221-3. PubMed ID: 23196570
    [Abstract] [Full Text] [Related]

  • 3. Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and Fused in Sarcoma (FUS).
    Nihei Y, Ito D, Suzuki N.
    J Biol Chem; 2012 Nov 30; 287(49):41310-23. PubMed ID: 23048034
    [Abstract] [Full Text] [Related]

  • 4. Stress granules in neurodegeneration--lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma.
    Bentmann E, Haass C, Dormann D.
    FEBS J; 2013 Sep 30; 280(18):4348-70. PubMed ID: 23587065
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?
    Baloh RH.
    Curr Opin Neurol; 2012 Dec 30; 25(6):701-7. PubMed ID: 23041957
    [Abstract] [Full Text] [Related]

  • 7. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).
    Bentmann E, Neumann M, Tahirovic S, Rodde R, Dormann D, Haass C.
    J Biol Chem; 2012 Jun 29; 287(27):23079-94. PubMed ID: 22563080
    [Abstract] [Full Text] [Related]

  • 8. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations.
    Daigle JG, Lanson NA, Smith RB, Casci I, Maltare A, Monaghan J, Nichols CD, Kryndushkin D, Shewmaker F, Pandey UB.
    Hum Mol Genet; 2013 Mar 15; 22(6):1193-205. PubMed ID: 23257289
    [Abstract] [Full Text] [Related]

  • 9. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS.
    Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, Gitler AD.
    PLoS Biol; 2011 Apr 15; 9(4):e1000614. PubMed ID: 21541367
    [Abstract] [Full Text] [Related]

  • 10. "STRESSED OUT": The role of FUS and TDP-43 in amyotrophic lateral sclerosis.
    Aksoy YA, Deng W, Stoddart J, Chung R, Guillemin G, Cole NJ, Neely GG, Hesselson D.
    Int J Biochem Cell Biol; 2020 Sep 15; 126():105821. PubMed ID: 32758633
    [Abstract] [Full Text] [Related]

  • 11. TDP-43 and FUS: a nuclear affair.
    Dormann D, Haass C.
    Trends Neurosci; 2011 Jul 15; 34(7):339-48. PubMed ID: 21700347
    [Abstract] [Full Text] [Related]

  • 12. Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration.
    Zhao B, Cowan CM, Coutts JA, Christy DD, Saraph A, Hsueh SCC, Plotkin SS, Mackenzie IR, Kaplan JM, Cashman NR.
    Acta Neuropathol Commun; 2023 Dec 18; 11(1):200. PubMed ID: 38111057
    [Abstract] [Full Text] [Related]

  • 13. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
    Verbeeck C, Deng Q, Dejesus-Hernandez M, Taylor G, Ceballos-Diaz C, Kocerha J, Golde T, Das P, Rademakers R, Dickson DW, Kukar T.
    Mol Neurodegener; 2012 Oct 10; 7():53. PubMed ID: 23046583
    [Abstract] [Full Text] [Related]

  • 14. A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43.
    Lanson NA, Maltare A, King H, Smith R, Kim JH, Taylor JP, Lloyd TE, Pandey UB.
    Hum Mol Genet; 2011 Jul 01; 20(13):2510-23. PubMed ID: 21487023
    [Abstract] [Full Text] [Related]

  • 15. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis.
    Farg MA, Soo KY, Warraich ST, Sundaramoorthy V, Blair IP, Atkin JD.
    Hum Mol Genet; 2013 Feb 15; 22(4):717-28. PubMed ID: 23172909
    [Abstract] [Full Text] [Related]

  • 16. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
    Neumann M, Valori CF, Ansorge O, Kretzschmar HA, Munoz DG, Kusaka H, Yokota O, Ishihara K, Ang LC, Bilbao JM, Mackenzie IR.
    Acta Neuropathol; 2012 Nov 15; 124(5):705-16. PubMed ID: 22842875
    [Abstract] [Full Text] [Related]

  • 17. TDP-43 and FUS en route from the nucleus to the cytoplasm.
    Ederle H, Dormann D.
    FEBS Lett; 2017 Jun 15; 591(11):1489-1507. PubMed ID: 28380257
    [Abstract] [Full Text] [Related]

  • 18. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins.
    Ratti A, Buratti E.
    J Neurochem; 2016 Aug 15; 138 Suppl 1():95-111. PubMed ID: 27015757
    [Abstract] [Full Text] [Related]

  • 19. FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.
    Deng Q, Holler CJ, Taylor G, Hudson KF, Watkins W, Gearing M, Ito D, Murray ME, Dickson DW, Seyfried NT, Kukar T.
    J Neurosci; 2014 Jun 04; 34(23):7802-13. PubMed ID: 24899704
    [Abstract] [Full Text] [Related]

  • 20. Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences.
    Neumann M.
    Rev Neurol (Paris); 2013 Oct 04; 169(10):793-8. PubMed ID: 24011641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.